Analyst Ratings For CELLECT BIOTECH/S ADR (NASDAQ:APOP)
Today, HC Wainwright reiterated its Buy rating on CELLECT BIOTECH/S ADR (NASDAQ:APOP) with a price target of $14.00.
There are 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on CELLECT BIOTECH/S ADR (NASDAQ:APOP) is Buy with a consensus target price of $14.00 per share, a potential 180.00% upside.
Some recent analyst ratings include
- 8/29/2018-CELLECT BIOTECH/S ADR (NASDAQ:APOP) had its Buy rating reiterated by HC Wainwright with a $14.00 price target
- 4/4/2017-CELLECT BIOTECH/S ADR (NASDAQ:APOP) had its Buy rating reiterated by Rodman & Renshaw with a $1.00 price target
About CELLECT BIOTECH/S ADR (NASDAQ:APOP)
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company was founded in 2011 and is headquartered in Kfar Saba, Israel.
Recent Trading Activity for CELLECT BIOTECH/S ADR (NASDAQ:APOP)
Shares of CELLECT BIOTECH/S ADR closed the previous trading session at 5,00 +0,22 4,60 % with shares trading hands.